Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SUPPLEMENTAL LICENSE AGREEMENT (NEXPLANON ROD TECHNOLOGY)Supplemental License Agreement • March 21st, 2022 • Organon & Co. • Pharmaceutical preparations • New York
This Supplemental License Agreement (this “Agreement”), dated as of 13 December 2021 (the “Effective Date”) is entered into by and between N.V. Organon, a private company with limited liability incorporated under the laws of the Netherlands (“Licensee”), and MERCK SHARP & DOHME B.V., a private company with limited liability incorporated under the laws of the Netherlands (“Licensor” and together with Licensee, each a “Party” and collectively, the “Parties”).
